The Molycorp Inc (NYSE:MCP) on May 7 announced financial and operating results for the first quarter 2014. The Company reported first quarter product sales volume of 3,518 metric tons (mt), a 10% increase over the fourth quarter 2013, at an average selling price (“ASP”) of $33.69 per kilogram. Net revenues for the first quarter were $118.5 million, a 4% decrease from the fourth quarter 2013. The Company reported a net loss of $0.40 per share for the quarter. The Company reported a net loss of $0.29 per share for the quarter on an adjusted non-GAAP basis. Molycorp Inc (NYSE:MCP) net profit margin is -90.00% and weekly performance is -7.54%. On last trading day company shares ended up $2.33. Analysts mean target price for the company is $4.10. Molycorp Inc (NYSE:MCP) distance from 50-day simple moving average is -26.47%.
Production at State College-based natural gas company Rex Energy Corporation (NASDAQ:REXX) is being impacted in the short term by a lack of pressure in Butler County with new wells coming on line.Rex (Nasdaq: REXX) said Monday it had placed 10 wells into production in and around Butler County, Pa., that are attached to the MarkWest Energy Partners’ Bluestone II processing facility. But the higher-pressure wells put into service have led Rex to constrain some production from its older, lower-pressure wells.Rex Energy Corporation (NASDAQ:REXX) shares fell -6.01% in last trading session and ended the day on $16.43. REXX Gross Margin is 76.00% and its return on assets is 0.70%. Rex Energy Corporation (NASDAQ:REXX) quarterly performance is -13.30%.
Palestine solidarity activists are celebrating huge victories over Sodastream International Ltd (NASDAQ:SODA) this week for the boycott, divestment and sanctions (BDS) campaign. Sodastream International Ltd (NASDAQ:SODA) shares moved down 2.51% in last trading session and was closed at $32.22, while trading in range of $32.03-$33.14. Sodastream International Ltd (NASDAQ:SODA) year to date performance is -35.09%.
Protalix BioTherapeutics (NYSE: PLX) announced that new clinical data on ELELYSO (taliglucerase alfa) will be presented at the European Working Group on Gaucher Disease 2014 11th Meeting being held June 25-28 in Haifa, Israel. ELELYSO, the Company’s first commercial product, is the first FDA-approved plant cell-based enzyme replacement therapy for Gaucher disease.Protalix BioTherapeutics Inc. (NYSEMKT:PLX) ended the last trading day at $3.37. Company weekly volatility is calculated as 3.75%. Protalix BioTherapeutics Inc. (NYSEMKT:PLX)showed a positive/negative weekly performance of -10.61%.